Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Tamoxifen Treatment of Breast Cancer Cells: Impact on Hedgehog/GLI1 Signaling.

Villegas VE, Rondón-Lagos M, Annaratone L, Castellano I, Grismaldo A, Sapino A, Zaphiropoulos PG.

Int J Mol Sci. 2016 Feb 27;17(3):308. doi: 10.3390/ijms17030308.

2.

Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.

Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder S.

Cancer Res. 2012 Oct 1;72(19):5048-59. doi: 10.1158/0008-5472.CAN-12-1248. Epub 2012 Aug 8.

3.

Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

Anticancer Res. 2006 May-Jun;26(3A):1773-84.

4.

Combination of cyclopamine and tamoxifen promotes survival and migration of mcf-7 breast cancer cells--interaction of hedgehog-gli and estrogen receptor signaling pathways.

Sabol M, Trnski D, Uzarevic Z, Ozretic P, Musani V, Rafaj M, Cindric M, Levanat S.

PLoS One. 2014 Dec 12;9(12):e114510. doi: 10.1371/journal.pone.0114510. eCollection 2014.

5.

Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells.

Diao Y, Azatyan A, Rahman MF, Zhao C, Zhu J, Dahlman-Wright K, Zaphiropoulos PG.

Oncotarget. 2016 Nov 1;7(44):71580-71593. doi: 10.18632/oncotarget.12259.

6.

A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.

Hatkevich T, Ramos J, Santos-Sanchez I, Patel YM.

Exp Cell Res. 2014 Oct 1;327(2):331-9. doi: 10.1016/j.yexcr.2014.05.017. Epub 2014 May 29.

PMID:
24881818
7.

Wwox suppresses breast cancer cell growth through modulation of the hedgehog-GLI1 signaling pathway.

Xiong A, Wei L, Ying M, Wu H, Hua J, Wang Y.

Biochem Biophys Res Commun. 2014 Jan 24;443(4):1200-5. doi: 10.1016/j.bbrc.2013.12.133. Epub 2014 Jan 4.

PMID:
24393846
8.

Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.

Zhang X, Wang ZY.

Endocrinology. 2013 Jun;154(6):1990-8. doi: 10.1210/en.2013-1116. Epub 2013 Apr 1.

PMID:
23546601
9.
10.

ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.

Heckler MM, Thakor H, Schafer CC, Riggins RB.

FEBS J. 2014 May;281(10):2431-42. doi: 10.1111/febs.12797. Epub 2014 Apr 28.

11.

GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.

Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G, Yang G.

Breast Cancer Res. 2013 Nov 29;15(6):R114. doi: 10.1186/bcr3581.

12.

In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.

Chen JL, Chang CJ, Wang JY, Wen CS, Tseng LM, Chang WC, Noomhorm N, Liu HJ, Chen WS, Chiu JH, Shyr YM.

Integr Cancer Ther. 2014 May;13(3):226-39. doi: 10.1177/1534735414520970. Epub 2014 Feb 12.

PMID:
24525674
13.

The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer.

Kameda C, Tanaka H, Yamasaki A, Nakamura M, Koga K, Sato N, Kubo M, Kuroki S, Tanaka M, Katano M.

Anticancer Res. 2009 Mar;29(3):871-9.

14.

The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.

He M, Fu Y, Yan Y, Xiao Q, Wu H, Yao W, Zhao H, Zhao L, Jiang Q, Yu Z, Jin F, Mi X, Wang E, Cui Z, Fu L, Chen J, Wei M.

Clin Sci (Lond). 2015 Nov;129(9):809-22. doi: 10.1042/CS20140592. Epub 2015 Jul 2.

PMID:
26201092
15.

Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation.

Sun Y, Wang Y, Fan C, Gao P, Wang X, Wei G, Wei J.

Mol Cancer. 2014 Jun 3;13:137. doi: 10.1186/1476-4598-13-137.

16.

AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.

Zhao W, Zhang Q, Kang X, Jin S, Lou C.

Biochem Biophys Res Commun. 2009 Mar 13;380(3):699-704. doi: 10.1016/j.bbrc.2009.01.155. Epub 2009 Jan 29.

PMID:
19285025
17.

Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.

Ahmed NS, Elghazawy NH, ElHady AK, Engel M, Hartmann RW, Abadi AH.

Eur J Med Chem. 2016 Apr 13;112:171-179. doi: 10.1016/j.ejmech.2016.02.026. Epub 2016 Feb 9.

PMID:
26896706
18.

Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells.

Kim HS, Tian L, Jung M, Choi SK, Sun Y, Kim H, Moon WK.

PLoS One. 2015 Oct 23;10(10):e0141110. doi: 10.1371/journal.pone.0141110. eCollection 2015.

19.

[Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].

Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F.

Bull Cancer. 1996 Oct;83(10):808-15. Review. French.

PMID:
8952630
20.

Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.

Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA.

Breast Cancer Res Treat. 2015 Nov;154(2):225-37. doi: 10.1007/s10549-015-3609-7. Epub 2015 Oct 20.

Supplemental Content

Support Center